The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).
Andrea Necchi
No relevant relationships to disclose
Patrizia Giannatempo
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Emanuela Fina
No relevant relationships to disclose
Nicola Nicolai
No relevant relationships to disclose
Marzia Pennati
No relevant relationships to disclose
Nadia Zaffaroni
No relevant relationships to disclose
Elena Farè
No relevant relationships to disclose
Luigi Piva
No relevant relationships to disclose
Davide Biasoni
No relevant relationships to disclose
Mario Catanzaro
No relevant relationships to disclose
Tullio Torelli
No relevant relationships to disclose
Silvia Stagni
No relevant relationships to disclose
Massimo Maffezzini
No relevant relationships to disclose
Maurizio Colecchia
No relevant relationships to disclose
Biagio Paolini
No relevant relationships to disclose
Vera Cappelletti
No relevant relationships to disclose
Maria Grazia Daidone
No relevant relationships to disclose
Alessandro M. Gianni
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose